drugset
drugset / Trial / NCT07141810

Efficacy and Safety of Early Antifibrotic Therapy for Non-progressive Fibrotic Interstitial Lung Disease

NCT07141810 ↗

Phase 4 Not yet recruiting 104 enrolled Shanghai Pulmonary Hospital, Shanghai, China
RandomizedParallel-groupSingle-blindTreatment

Summary

Early antifibrotic therapy for f-ILD

Timeline

Start
2025-10-01
Primary completion
2028-04-30
Completion
2028-05-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pirfenidone Small molecule — —
Comparator nidanib Unknown — —

Indications

interstitial lung disease